šŸ“£ VC round data is live. Check it out!

Equasens Valuation Multiples

Discover Equasens' revenue and EBITDA valuation multiples and M&A history, alongside public comparables like Echo IQ, Phreesia, Craneware, Yidu Tech and more.

Equasens Overview

About Equasens

Equasens is engaged in the European healthcare sector, providing software solutions to all healthcare professionals (pharmacists, primary care practitioners, hospitals, Hospital-at-Home structures, retirement homes, health centers) and patients in both primary and secondary care sectors. The various activities that the company is involved in include: pharmacy software publishing and integration, publishing of IT solutions for health and medical/social establishments, and development of solutions and infrastructures for e-Health. With operations in France (its key revenue-generating market), Italy, Belgium, Germany, Ireland, and the United Kingdom, it is developing the healthcare platform and an ecosystem in France and Europe, benefiting people by making itsĀ technology services available.


Founded

1996

HQ

France

Employees

1.4K

Financials (LTM)

Revenue: $284M
EBITDA: $79M

EV

$640M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Equasens Financials

Equasens reported last 12-month revenue of $284M and EBITDA of $79M.

In the same LTM period, Equasens generated $79M in EBITDA and $49M in net income.

Revenue (LTM)


Equasens P&L

In the most recent fiscal year, Equasens reported revenue of $275M and EBITDA of $83M.

Equasens is profitable as of last fiscal year, with gross margin of 69%, EBITDA margin of 30%, and net margin of 17%.

See analyst estimates for Equasens
LTMLast FY202320242025202620272028
Revenue$284M$275M$256M$252M$275M
Gross Profit-$189M$175M$173M$189M
Gross Margin-69%69%69%69%
EBITDA$79M$83M$83M$73M$83M
EBITDA Margin28%30%33%29%30%
EBIT Margin21%20%25%21%20%
Net Profit$49M$46M$55M$42M$46M
Net Margin17%17%21%17%17%
Net Debt-$23M---

Financial data powered by Morningstar, Inc.

Equasens Stock Performance

Equasens has current market cap of $671M, and enterprise value of $640M.

Market Cap Evolution


Equasens' stock price is $44.62.

Equasens share price decreased by 2.7% in the last 30 days, and by 20.9% in the last year.

Equasens has an EPS (earnings per share) of $3.04.

See more trading valuation data for Equasens
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$640M$671M-2.7%-2.7%-5.8%-20.9%$3.04

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Equasens Valuation Multiples

Equasens trades at 2.3x EV/Revenue multiple, and 8.1x EV/EBITDA.

See NTM and 2027E valuation multiples for Equasens

EV / Revenue (LTM)


Equasens Financial Valuation Multiples

As of June 3, 2026, Equasens has market cap of $671M and EV of $640M.

Equasens has a P/E ratio of 13.8x.

LTMLast FY202320242025202620272028
EV/Revenue2.3x2.3x2.5x2.5x2.3x
EV/EBITDA8.1x7.8x7.7x8.7x7.8x
EV/EBIT10.9x11.5x9.9x12.1x11.5x
EV/Gross Profit-3.4x3.7x3.7x3.4x
P/E13.8x14.7x12.3x15.9x14.7x
EV/FCF12.1x11.7x14.0x15.3x11.7x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Equasens Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Equasens Margins & Growth Rates

Equasens grew revenue by 10% and EBITDA by 1% in the last fiscal year.

In the most recent fiscal year, Equasens reported gross margin of 69%, EBITDA margin of 30%, and net margin of 17%.

See estimated margins and future growth rates for Equasens

Equasens Margins

Last FY202420252026202720282029
Gross Margin69%69%69%-
EBITDA Margin30%29%30%28%
EBIT Margin20%21%20%21%
Net Margin17%17%17%18%
FCF Margin20%17%20%18%

Equasens Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth10%(1%)9%10%
Gross Profit Growth-(1%)9%-
EBITDA Growth1%(12%)13%1%
EBIT Growth14%(19%)6%14%
Net Profit Growth16%(23%)9%16%
FCF Growth(2%)(9%)31%(2%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Equasens Operational KPIs

Equasens' revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.

Equasens' Rule of 40 is 38% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Equasens' Rule of X is 53% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Equasens
LTMLast FY202320242025202620272028
Rule of 4037%38%---
Bessemer Rule of X51%53%---
Revenue per Employee-$0.2M---
Opex per Employee-$0.1M---
Opex to Revenue-49%43%48%49%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Equasens Competitors

Equasens competitors include Echo IQ, Phreesia, Craneware, Yidu Tech, HealthStream, Shang Gong Group, Lunit, RaySearch Labs, Artrya and Guiyang Longmaster.

Most Equasens public comparables operate across Healthcare Software, B2B SaaS, Vertical SaaS and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Echo IQ8817.5x1192.6x(150.6x)(122.3x)
Phreesia1.4x1.3x6.5x5.9x
Craneware3.4x3.1x10.7x10.0x
Yidu Tech4.0x-(31.6x)-
HealthStream2.2x2.2x9.5x9.3x
Shang Gong Group1.0x-22.6x-
Lunit14.8x13.5x(113.5x)(23.7x)
RaySearch Labs5.2x5.2x12.0x11.7x

This data is available for Pro users. Sign up to see all Equasens competitors and their valuation data.

Start Free Trial

Acquisitions by Equasens

Equasens has acquired 2 companies to date.

Last acquisition by Equasens was on January 5th 2026. Equasens acquired Erevo for $22M (EV/Revenue multiple available to Pro users).

See M&A valuation multiples

Latest Acquisitions by Equasens

Erevo
Calimed Health
Description
Erevo is a French professional training company creating online courses for healthcare workers including nurses, general practitioners, podiatrists, physiotherapists, and dental surgeons.
Calimed Health is a French software provider decentralizing medical information and scheduling management for healthcare professionals. Based in Lyon, the platform enables secure sharing of patient records, appointment booking, and teleconsultation across clinics and hospitals. It complies with French data protection standards like RGPD and HDS hosting requirements, supporting multidisciplinary teams in primary care and specialties. The service streamlines administrative workflows while maintaining interoperability with national health systems such as Mon Espace SantƩ.
HQ CountryFranceFrance
HQ City
-
Marseille
Deal Date5 Jan 202627 Dec 2024
Valuation$22Mundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Equasens acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Equasens

When was Equasens founded?Equasens was founded in 1996.
Where is Equasens headquartered?Equasens is headquartered in France.
How many employees does Equasens have?As of today, Equasens has over 1K employees.
Who is the CEO of Equasens?Equasens' CEO is Denis Supplisson.
Is Equasens publicly listed?Yes, Equasens is a public company listed on Euronext Paris.
What is the stock symbol of Equasens?Equasens trades under EQS ticker.
When did Equasens go public?Equasens went public in 2000.
Who are competitors of Equasens?Equasens main competitors include Echo IQ, Phreesia, Craneware, Yidu Tech, HealthStream, Shang Gong Group, Lunit, RaySearch Labs, Artrya, Guiyang Longmaster.
What is the current market cap of Equasens?Equasens' current market cap is $671M.
What is the current revenue of Equasens?Equasens' last 12 months revenue is $284M.
What is the current revenue growth of Equasens?Equasens revenue growth (NTM/LTM) is 9%.
What is the current EV/Revenue multiple of Equasens?Current revenue multiple of Equasens is 2.3x.
What is the current EBITDA of Equasens?Equasens' last 12 months EBITDA is $79M.
What is Equasens' EBITDA margin?Equasens' last 12 months EBITDA margin is 28%.
What is the current EV/EBITDA multiple of Equasens?Current EBITDA multiple of Equasens is 8.1x.
What is the current FCF of Equasens?Equasens' last 12 months FCF is $53M.
What is Equasens' FCF margin?Equasens' last 12 months FCF margin is 19%.
What is the current EV/FCF multiple of Equasens?Current FCF multiple of Equasens is 12.1x.
How many companies Equasens has acquired to date?As of June 2026, Equasens has acquired 2 companies.
What was the largest acquisition by Equasens?$22M acquisition of Erevo on 5th January 2026 was the largest M&A Equasens has done to date.
What companies Equasens acquired?Equasens acquired Erevo and Calimed Health.
In how many companies Equasens has invested to date?Equasens hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Equasens

Lists including Equasens

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial